73 related articles for article (PubMed ID: 8778810)
1. Environmental causes and molecular biology of breast cancer: future research directions.
Jahnke GD; Barrett JC
Prog Clin Biol Res; 1996; 394():455-69. PubMed ID: 8778810
[No Abstract] [Full Text] [Related]
2. Xenoestrogens, biotransformation, and differential risks for breast cancer.
Rogan E
Altern Ther Health Med; 2007; 13(2):S112-21. PubMed ID: 17405688
[No Abstract] [Full Text] [Related]
3. Possible implication of environmental hormones in the recent risk increase of cancers of the skin and the liver, but not of the female breast worldwide.
Kodama M; Murakami M; Kodama T
Anticancer Res; 1999; 19(1B):789-98. PubMed ID: 10216494
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer oestrogen independence mediated by BCAR1 or BCAR3 genes is transmitted through mechanisms distinct from the oestrogen receptor signalling pathway or the epidermal growth factor receptor signalling pathway.
Dorssers LC; van Agthoven T; Brinkman A; Veldscholte J; Smid M; Dechering KJ
Breast Cancer Res; 2005; 7(1):R82-92. PubMed ID: 15642172
[TBL] [Abstract][Full Text] [Related]
5. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk.
Massarweh S; Schiff R
Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S15-24. PubMed ID: 17259554
[TBL] [Abstract][Full Text] [Related]
6. Altered gene expression in drug-resistant human breast cancer cells.
Wosikowski K; Schuurhuis D; Kops GJ; Saceda M; Bates SE
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2405-14. PubMed ID: 9815641
[TBL] [Abstract][Full Text] [Related]
7. Antisense estrogen receptor RNA expression increases epidermal growth factor receptor gene expression in breast cancer cells.
deFazio A; Chiew YE; McEvoy M; Watts CK; Sutherland RL
Cell Growth Differ; 1997 Aug; 8(8):903-11. PubMed ID: 9269899
[TBL] [Abstract][Full Text] [Related]
8. Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators.
Schiff R; Massarweh SA; Shou J; Bharwani L; Arpino G; Rimawi M; Osborne CK
Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():10-20. PubMed ID: 16273359
[TBL] [Abstract][Full Text] [Related]
9. Wnt signalling via the epidermal growth factor receptor: a role in breast cancer?
Musgrove EA
Breast Cancer Res; 2004; 6(2):65-8. PubMed ID: 14979908
[TBL] [Abstract][Full Text] [Related]
10. Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer.
Kim HJ; Cui X; Hilsenbeck SG; Lee AV
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1013s-1018s. PubMed ID: 16467118
[TBL] [Abstract][Full Text] [Related]
11. Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression.
Umemura S; Takekoshi S; Suzuki Y; Saitoh Y; Tokuda Y; Osamura RY
Oncol Rep; 2005 Aug; 14(2):337-43. PubMed ID: 16012712
[TBL] [Abstract][Full Text] [Related]
12. Induction of aromatase (CYP19) expression in breast cancer cells through a nongenomic action of estrogen receptor alpha.
Kinoshita Y; Chen S
Cancer Res; 2003 Jul; 63(13):3546-55. PubMed ID: 12839940
[TBL] [Abstract][Full Text] [Related]
13. Role of epidermal growth factor receptor and STAT-3 activation in autonomous proliferation of SUM-102PT human breast cancer cells.
Sartor CI; Dziubinski ML; Yu CL; Jove R; Ethier SP
Cancer Res; 1997 Mar; 57(5):978-87. PubMed ID: 9041204
[TBL] [Abstract][Full Text] [Related]
14. Estrogen receptor-positive human epithelial ovarian carcinoma cells respond to the antitumor drug suramin with increased proliferation: possible insight into ER and epidermal growth factor signaling interactions in ovarian cancer.
Kalli KR; Bradley SV; Fuchshuber S; Conover CA
Gynecol Oncol; 2004 Sep; 94(3):705-12. PubMed ID: 15350362
[TBL] [Abstract][Full Text] [Related]
15. Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program.
Lane HA; Lebwohl D
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S18-25. PubMed ID: 16730273
[TBL] [Abstract][Full Text] [Related]
16. Workshop report: identification of research needs breast cancer etiology.
Friedenreich C; Marrett LD;
Chronic Dis Can; 2001; 22(2):41-9. PubMed ID: 11525719
[TBL] [Abstract][Full Text] [Related]
17. [Modern approaches to estrogen-independent growth of breast tumor].
Krasil'nikov MA
Vopr Onkol; 2004; 50(4):399-405. PubMed ID: 15605761
[No Abstract] [Full Text] [Related]
18. Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR.
Hicks DG; Short SM; Prescott NL; Tarr SM; Coleman KA; Yoder BJ; Crowe JP; Choueiri TK; Dawson AE; Budd GT; Tubbs RR; Casey G; Weil RJ
Am J Surg Pathol; 2006 Sep; 30(9):1097-104. PubMed ID: 16931954
[TBL] [Abstract][Full Text] [Related]
19. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.
Cui X; Schiff R; Arpino G; Osborne CK; Lee AV
J Clin Oncol; 2005 Oct; 23(30):7721-35. PubMed ID: 16234531
[TBL] [Abstract][Full Text] [Related]
20. Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors.
Creighton CJ; Hilger AM; Murthy S; Rae JM; Chinnaiyan AM; El-Ashry D
Cancer Res; 2006 Apr; 66(7):3903-11. PubMed ID: 16585219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
